Rucaparib phosphate

Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
AG 014699; Rucaparib, PF-01367338
API & Intermediates
KAPI1F14
459868-92-9
 
9931953

image-155171-Trimethyl(trifluoromethyl)silane_reagent.png
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
Rucaparib phosphate
C19H18FN3O•H3PO4
421.36
≥99%(HPLC)
Pale Yellow Solid
>173°C
500mg,1g,10g,25g,50g,100g and 500g
-20°C Freezer
Rucaparib phosphate (also known as AG 014699; Rucaparib, PF-01367338) is a Poly(ADP-ribose) polymerases (PARPs) inhibitor used as an anti-cancer agent.
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. [1]
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. [2]
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. [3]
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. [4]
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? [5]
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. [6]
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. [7]
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. [8]
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. [9]
Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice. [10]
References:
[1] B.P.Rowe, et al, Breast Cancer Res., 2010, 12(2), pp 1-11.
[2] R.A.Daniel, et al, Br. J. Cancer, 2010, 103(10), pp 1588-1596.
[3] Y.Yuan, et al, J. Hematol. Oncol., 2011, 4(16), pp 1-14.
[4] M. Javle, et al, Ther. Adv. Med. Oncol., 2011, 3(6), pp 257-267.
[5] R.Plummer, et al, Breast cancer Res., 2011, 13(4), pp 1-6.
[6] N.Johnson, et al, Nature Medicine, 2011, 17(7),pp 875-882.
[7] Y.Drew, et al,  J. Natl. Cancer Inst., 2011, 103(4), pp 334-346.
[8] Y.Drew, et al, Br. J. Cancer., 2016, 114(7), pp 723-730.
[9] M.Zanjirband, et al, Oncotarget, 2017, 8(41), pp 69779-69796.
[10] S.Huang, et al, J. Pharmacol. Exp. Ther., 2018, 364(3), pp 452-461.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Not classified as a dangerous goods



NONH for all modes of transport
Sales restrictions may apply.
1. Product Specification
2. Safety Data Sheet
Available on request.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.